Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
KYOWA KIRIN, INC via KYOWA KIRIN, INC
2026 · third_quarter · Q3
Trade/tariffs, pharmaceutical pricing/value and rare disease issues
Tariffs & Trade policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYOWA KIRIN, INC via
Source: Senate LDA
2026 · second_quarter · Q2
Trade/tariffs, pharmaceutical pricing/value and rare disease issues
Tariffs & Trade policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYOWA KIRIN, INC via KYOWA KIRIN, INC
2026 · first_quarter · Q1
Trade/tariffs and pharmaceutical pricing/value
Tariffs & Trade policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYOWA KIRIN, INC via KYOWA KIRIN, INC
2025 · fourth_quarter · Q4
Trade/tariffs and pharmaceutical pricing/value
Tariffs and trade policy
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
KYOWA KIRIN, INC via KYOWA KIRIN, INC
2025 · third_quarter · Q3
Trade/tariffs and pharmaceutical pricing/value
Tariffs and trade policy
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
KYOWA KIRIN, INC via KYOWA KIRIN, INC
2025 · second_quarter · Q2
FDA modernization policy issues. General issues related to rare disease and clinical trials. General issues related to diagnostics for patients with rare diseases. Issues related to drug pricing. Issues related to reform of pharmacy benefit managers. Issues related to trade. Issues related to Newborn Screening and Genetic Testing.
Issues related to trade.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYOWA KIRIN, INC via KYOWA KIRIN, INC
2025 · second_quarter · RR
FDA modernization policy issues General issues related to rare disease and clinical trials General issues related to diagnostics for patients with rare diseases Issues related to drug pricing Issues related to reform of pharmacy benefit managers Issues related to trade Issues related to Newborn Screening and Genetic Testing